<DOC>
	<DOCNO>NCT00602511</DOCNO>
	<brief_summary>The purpose study compare thalidomide + dexamethasone bortezomib + dexamethasone patient multiple myeloma refractory melphalan therapy . The main goal find two 2 : nd line regimens offer patient best chance response long duration good quality life possible .</brief_summary>
	<brief_title>Thalidomide Versus Bortezomib Melphalan Refractory Myeloma</brief_title>
	<detailed_description>The study open randomize multicentre study patient multiple myeloma refractory melphalan therapy randomize bortezomib thalidomide therapy , arm addition dexamethasone . In case failure initially give treatment patient cross alternative treatment . The number patient need calculated 300 , base upon hypothesis 50 % difference progression free survival , significance level 95 % power 80 % . With 12 patient recruit month 25 month 4 month follow-up last included patient , total study time 29 month . The dose regimen bortezomib thalidomide follow general clinical praxis regard recommendation optimal dose Nordic country . Evaluation response toxicity perform every 3 week least 12 week , thereafter every 6 week . Evaluation efficacy do accord The International Myeloma Working Group Uniform Response Criteria . Evaluation toxicity do CTCAE grade . Evaluation quality life do EORTC QLQ30 questionnaires addition myeloma specific MY-24 module mail patient predetermine interval study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Treatment demand multiple myeloma Refractoriness melphalan Acceptance rule prevention pregnancy Previous treatment bortezomib , thalidomide , lenalidomide Sensory neuropathy grade III neuropathic pain grade II Severe concomitant disorder , e.g . malignancy severe heart disease Transformation plasma cell leukemia aggressive lymphoma Frequent visit bortezomib injection feasible Anticipated nonadherence study protocol Pregnancy Anticipated nonadherence rule prevention pregnancy Severe thrombocytopenia ( Thrombocyte count le 25000/microliter )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Melfalan refractory multiple myeloma</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Relapsing</keyword>
	<keyword>Refractory</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Randomized clinical trial</keyword>
</DOC>